GPP
BCRX icon

Great Point Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Great Point Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-725,000
Closed -$4.59M – 41
2016
Q4 		$4.59M Hold
725,000
– – 0.94% 23
2016
Q3 		$3.2M Buy
+725,000
New +$2.9M 0.82% 21

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Great Point Partners's BCRX Position: Q2 2019 in Review

Great Point Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2019, closing a stake of 5,955,762 shares — an estimated $48.5M sold.

Great Point Partners first reported a position in BCRX in Q3 2017 and held it in 7 quarters. The position peaked at $61.5M in Q4 2018. 116 funds tracked by Wall St. Rank hold BCRX as of Q2 2019.

  • Great Point Partners reported no remaining BioCryst Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Great Point Partners sold 5,955,762 BioCryst Pharmaceuticals shares in Q2 2019, an estimated $48.5M.
  • Great Point Partners first reported a position in BioCryst Pharmaceuticals in Q3 2017 and held it in 7 quarters.
  • Great Point Partners's BioCryst Pharmaceuticals position peaked at $61.5M in Q4 2018.
  • 116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2019.

Based on Great Point Partners's 13F filing for Q2 2019, filed 14 Aug 2019.